| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_797d0fdb51b9056485169b0151d1688d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84bbd0b1062cc7ed1acf530b9d9536fe |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2001-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3403a81bc31a6576fcdb07a17846867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_312625e61c7c4738de8f426fea037bbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fa3a066f5a33d2b8e03a9014bc6e296
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_994db7c025681ae3ec48ba6b854971e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0668bb8146364dbb4819b337faa1f8aa |
| publicationDate |
2003-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1325335-A2 |
| titleOfInvention |
Methods for diagnosing and treating huntington's disease |
| abstract |
The invention is based on the identification of abnormal behaviour of the adenosine A2A receptor, both as regards the bond to specific ligands and its coupling to the adenylate cyclase system characteristic of cells genetically predisposed to develop Huntington's Disease and of circulating cells in patients affected by this disease. The present invention uses this abnormal behaviour as a diagnostic marker for early detection of the onset and/or progression of this disease, and as a pharmacological target to inhibit to delay progression of the pathology. The invention consists in an in-vitro method for diagnosing Huntington's disease based on assessment of the increase in the number of A2A receptors for adenosine and/or of the abnormal activity of adenylate cyclase, and in the use of drugs that inhibit this activity, for the prevention and/or treatment of this disease. |
| priorityDate |
2000-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |